ReviewHeart failure reviews2021
Soluble CD146-an underreported novel biomarker of congestion: a comment on a review concerning congestion assessment and evaluation in acute heart failure.
Review in Heart failure reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Biological properties of soluble CD146 and its role and mechanisms in disease progression.Frontiers in immunology · 2026Review
- Soluble CD146 in Heart Failure: Pathophysiological Role and Diagnostic Potential.Biomedicines · 2025Review
- Observational
- Knockdown of CD146 promotes endothelial-to-mesenchymal transition via Wnt/β-catenin pathway.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In spite of high prevalence, congestion remains a poorly understood phenomenon in heart failure pathophysiology. Its negative impact on outcome has been widely recognised. Still, data from various registries reveal the failure of the contemporary treatment strategies to overcome congestion. This shortcoming is closely related to the fact that there are no universe means for congestion assessment and grading, making it a difficult process to recognise. CD146 is a novel blood biomarker of congestion that has been shown to reflect intravascular fluid accumulation in a number of experimental and clinical studies. This observation deserves special attention, given the huge gap of knowledge about decongestive strategies in acute and chronic heart failure. Randomised clinical trials testing the effect of CD146-guided management intervention are urgently needed to estimate its value in heart failure care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.